MELATONIN M/R 1mg and 5mg tablets (Slenyto®)

Clinical Indication

Insomnia for children aged 2-18 years with Autism Spectrum Disorder and or Smith-Magenis syndrome

Date of classification

August 2019

Review date

December 2021


Medicines initiated or recommended by a specialist service for prescribing in primary care which do not require initiation or ongoing oversight by the specialist. There are no specific paperwork requirements between provider organisations and a verbal request may be acceptable through advice and guidance as long enough information is provided so that the transfer of care is safe.